Tirzepatide's Effectiveness in HFpEF linked to Baseline BMI and Fat Distribution: SUMMIT Trial

This secondary analysis examined whether baseline severity of obesity (BMI) or distribution of obesity (WHR) had an effect on endpoints like cardiovascular death or HF deterioration, quality of life (KCCQ-CSS), 6-minute walk distance (6MWD), C-reactive protein (CRP), and body weight (BW). Cox regression and mixed-effects models were employed. Investigators also assessed the relationship between the magnitude of weight reduction and waist circumference decrease with tirzepatide and improvements in the major endpoints.

Key Findings:

• Younger, female patients with higher BMI had more volume overload, inflammation, and physical restriction. In BMI tertiles, tirzepatide always decreases cardiovascular death or worsening of HF risk with no heterogeneity by BMI or WHR stratum.

More increase in 6-minute walk distance:

• Estimated treatment difference (ETD): 9.9 m (low BMI) vs 26.3 m (middle BMI) vs 37.5 m (high BMI); P = 0.025

Greater weight loss:

• ETD: −10.7% vs −11.8% vs −14.4%; P = 0.006

Greater decrease in systolic BP:

• ETD: −1.00 vs −6.65 vs −6.62 mm Hg; P = 0.035

Trend towards improved quality of life (KCCQ-CSS):

• P = 0.097

In HFpEF patients with obesity, tirzepatide decreased the risk of heart failure events and cardiovascular death independent of baseline BMI or WHR. Increased BMI and WHR were linked to younger age, female gender, increased inflammatory burden, renal dysfunction, and poorer exercise capacity. These results validate the utilization of tirzepatide as an efficacious therapeutic agent for enhancing HFpEF outcomes in obese patients.

Reference:

Borlaug, B. A., Zile, M. R., Kramer, C. M., Ye, W., Ou, Y., Hurt, K., Murakami, M., Packer, M., & SUMMIT Trial Study Group. (2025). Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: The SUMMIT trial. Journal of the American College of Cardiology, 86(4), 242–255. https://doi.org/10.1016/j.jacc.2025.04.059